Search results for " Combination"

showing 10 items of 923 documents

New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin

2015

Oral fluoropyrimidines have been available for more than 10 years. Capecitabine is well established in treating solid tumors in Europe. S-1 (Teysuno®), an oral formulation containing the 5-fluorouracil (5-FU) prodrug tegafur and the two enzyme modulators gimeracil and oteracil, has not been available in non-Asia countries until recently. In Japan, S-1 in combination with cisplatin is the recommended first-line treatment in patients with gastric cancer. In Europe, the first trials with S-1 were disappointing due to high unacceptable incidences of adverse events. Pharmacokinetic studies showed differences in Asian and Caucasian patients; therefore, a new non-Asian study program was initiated,…

0301 basic medicineOncologymedicine.medical_specialtyAdministration OralAntineoplastic AgentsTegafurCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineDrug DiscoverymedicineClinical endpointHumansPharmacology (medical)Survival rateNeoplasm StagingPharmacologyCisplatinbusiness.industryCancerGeneral Medicinemedicine.diseaseHematologic DiseasesSurvival Rate030104 developmental biologyInfectious DiseasesOncologyTolerability030220 oncology & carcinogenesisDrug Therapy CombinationFluorouracilCisplatinbusinessmedicine.drugTegafur/gimeracil/oteracilChemotherapy
researchProduct

CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy

2018

ABSTRACT The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe’s largest meeting series of its kind, took place in Mainz, Germany from 15–17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among more than 700 scientists under the motto “Pushing Frontiers in Cancer Immunotherapy”. This meeting report is a summary of some of the CIMT 2018 highlights.

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicineNeoplasmsmedicineTumor MicroenvironmentImmunology and AllergyAnimalsHumansPersonalized therapytumor vaccinationPharmacologypersonalized therapyTumor microenvironmentcancer immunotherapybusiness.industryVaccinationCIMTcellular therapyCongresses as TopicXenograft Model Antitumor AssaysDisease Models Animal030104 developmental biologycheckpoint blockadeDrug Therapy CombinationImmunotherapybusinessHuman Vaccines & Immunotherapeutics
researchProduct

Cytotoxic activity of medicinal plants of the Kakamega County (Kenya) against drug-sensitive and multidrug-resistant cancer cells

2018

Abstract Ethnopharmacological relevance The geographical location of Kakamega County proximal to the Kakamega Rain Forest in Kenya and its rich flora represents an interesting resource of traditional medicinal plants. The medicinal plants in the present study are traditionally used to treat cancer in Kakamega County as recorded in published literature. Aim of the study Due to multidrug resistance (MDR) and severe side effects of currently used drugs in clinical oncology, new candidate compounds are urgently required to improve treatment outcome. The present study explored the in vitro cytotoxic potential of 34 organic and 19 aqueous extracts of Kakamega medicinal plants towards sensitive an…

0301 basic medicinePhyllanthusCell SurvivalDrug resistancePharmacognosyInhibitory Concentration 5003 medical and health sciences0302 clinical medicineCell Line TumorOxazinesDrug DiscoveryHarunganaATP Binding Cassette Transporter Subfamily G Member 2HumansATP Binding Cassette Transporter Subfamily B Member 1Medicinal plantsMedicine African TraditionalPharmacologyPrunus africanaPlants MedicinalbiologyTraditional medicineBridelia micranthabiology.organism_classificationAntineoplastic Agents PhytogenicNeoplasm ProteinsErbB ReceptorsGene Expression Regulation NeoplasticMultiple drug resistance030104 developmental biologyXanthenesDrug Resistance Neoplasm030220 oncology & carcinogenesisDrug Therapy CombinationJournal of Ethnopharmacology
researchProduct

Functional characterization of a novel 3D model of the epithelial-mesenchymal trophic unit

2017

Background/Aim: Epithelial-mesenchymal communication plays a key role in tissue homeostasis and abnormal signaling contributes to chronic airways disease such as COPD. Most in vitro models are limited in complexity and poorly represent this epithelial-mesenchymal trophic unit. We postulated that cellular outgrowth from bronchial tissue would enable development of a mucosal structure that recapitulates better in vivo tissue architecture. Materials and Methods: Bronchial tissue was embedded in Matrigel and outgrowth cultures monitored using time-lapse microscopy, electrical resistance, light and electron microscopy. Cultures were challenged repetitively with cigarette smoke extract (CSE). Res…

0301 basic medicinePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyClinical BiochemistryBronchiRespiratory MucosaBiologyImmunofluorescenceModels Biologicalfibroblastbronchial03 medical and health sciencesIn vivoSmokemedicineHumansFibroblastMolecular BiologyCells CulturedTissue homeostasisMicroscopyMatrigelECMelectron microscopymedicine.diagnostic_testcigarette smokeMesenchymal stem cellEpithelial CellsMesenchymal Stem CellsEpitheliumCell biologyDrug Combinations030104 developmental biologymedicine.anatomical_structurein vitro modelMotile ciliumProteoglycansCollagenLamininepitheliumExperimental Lung Research
researchProduct

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

2019

AbstractWe reported the efficacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in patients treated in the Italian compassionate-use program. 275 patients were included (202 male-73.5%, mean age: 57.4 years, 62 HIV-coinfected, 94 with recurrence of hepatitis C post-OLT). Forty-nine patients (17.8%) had Child-Pugh B, Genotype(G) distribution was: G1a:72 patients (26.2%), G1b:137 (49.8%); G3:40 (14.5%) and G4:26 (9.5%). Patients received DCV with sofosbuvir(SOF) (n = 221, 129 with ribavirin(RBV) or with simeprevir (SMV) or asunaprevir (ASU) (n = 54, 19 with RBV) for up to 24 weeks. Logistic regression was used to identify baseline characteristics associated with sustai…

0301 basic medicineSimeprevirLiver CirrhosisMalePyrrolidinesSofosbuvirSustained Virologic Responselcsh:MedicineSettore MED/05Gastroenterologychemistry.chemical_compound0302 clinical medicineLiver Function TestsINFECTIONMedicinePLUS SOFOSBUVIRlcsh:ScienceSulfonamidesMultidisciplinaryImidazolesValineHepatitis CMiddle AgedTreatment OutcomeItalySAFETYHCVSUSTAINED VIROLOGICAL RESPONSEDrug Therapy CombinationFemaleRIBAVIRINSettore BIO/19 - MICROBIOLOGIA GENERALECHRONIC HEPATITIS-Cmedicine.drugAdultmedicine.medical_specialtyDaclatasvirDrug-Related Side Effects and Adverse ReactionsAntiviral AgentsArticle03 medical and health sciencesInternal medicineHumansAgedADVANCED LIVER-DISEASEbusiness.industryRibavirinVIRUS GENOTYPE 3lcsh:RHepatitis C ChronicHCV HIV Daclatasvirmedicine.diseaseIsoquinolinesEFFICACYRegimen030104 developmental biologychemistryAsunaprevirlcsh:QLiver functionCarbamatesSofosbuvirbusiness030217 neurology & neurosurgeryScientific Reports
researchProduct

NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved.

2021

Due to the improved effectiveness and safety of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection has become a manageable, chronic condition rather than a mortal disease. However, HIV patients are at increased risk of experiencing non-AIDS-defining illnesses, with liver-related injury standing out as one of the leading causes of death among these patients. In addition to more HIV-specific processes, such as antiretroviral drug-related toxicity and direct injury to the liver by the virus itself, its pathogenesis is related to conditions that are also common in the general population, such as alcoholic and non-alcoholic fatty liver disease, viral hepatitis, and age…

0301 basic medicinehepatotoxicityNevirapineEfavirenzQH301-705.5030106 microbiologyEtravirinecARTReviewBioinformaticsliver03 medical and health scienceschemistry.chemical_compoundLiver disease0302 clinical medicineDoravirinemedicineAnimalsHumans030212 general & internal medicineBiology (General)antiretroviral drugsbusiness.industryFatty livervirus diseasesHIVGeneral Medicinemedicine.diseasechemistryRilpivirineChronic DiseaseReverse Transcriptase InhibitorsDrug Therapy CombinationDILIChemical and Drug Induced Liver InjuryViral hepatitisbusinessmedicine.drugCells
researchProduct

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

2021

Background & Aims A number of double, triple, and quadruple therapies have been proposed as first-line empiric treatments for Helicobacter pylori infection. However, knowledge of their worldwide and regional comparative efficacy is lacking. We examined the comparative effectiveness of all empirically used first-line regimens tested against standard triple treatment using a network meta-analysis of published randomized controlled trials. Methods Data extracted from eligible randomized controlled trials were entered into a Bayesian network meta-analysis to investigate the comparative efficacy of H pylori infection empiric first-line regimens and to explore their effectiveness rank order. The …

0301 basic medicinemedicine.medical_specialtyComparative Effectiveness ResearchTime FactorsEfficacyVonoprazanSettore MED/12 - GASTROENTEROLOGIANetwork Meta-Analysislaw.inventionHelicobacter Infections03 medical and health sciences0302 clinical medicineRandomized controlled trialDrug TherapyLevofloxacinlawInternal medicinemedicineHumansFirst-Line RegimensRandomized Controlled Trials as TopicHepatologybiologyHelicobacter pyloribusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyBayes TheoremProton Pump InhibitorsOdds ratioHelicobacter pyloribiology.organism_classificationConfidence intervalAnti-Bacterial AgentsTreatmentRegimen030104 developmental biologyTreatment OutcomeMeta-analysisCombination030211 gastroenterology & hepatologyDrug Therapy Combinationbusinessmedicine.drug
researchProduct

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct

Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

2021

Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction of anti-tumor immune responses. Oncolytic viruses can also be engineered to genetically deliver therapeutic proteins for direct or indirect cancer cell killing. In this review—as part of the special edition on “State-of-the-Art Viral Vector Gene Therapy in Germany”—the German community of virotherapists provides an overview of their recent research activities that cover endeavors from screening and engineering viruses as oncolytic cancer therapeutics to their cli…

0301 basic medicinemedicine.medical_treatmentGenetic enhancementvirus targetingMedizinReviewcombination therapychemistry.chemical_compoundDDC 570 / Life sciencesClinical trials0302 clinical medicineKlinisches ExperimentGermanyNeoplasmsMedicineimmunotherapy ; therapeutic transgene ; combination therapy ; Virustherapie ; clinical trials ; virus engineering ; oncolytic virus ; research in Germany ; virus targeting ; virotherapyOncolytic VirotherapyClinical Trials as Topicvirus engineeringKombinationstherapieQR1-5023. Good healthOncolytic VirusesInfectious Diseases030220 oncology & carcinogenesisImmunotherapyvirotherapyGenetic Engineeringresearch in GermanyMicrobiologyVirusViral vector03 medical and health sciencesImmune systemddc:570VirologyAnimalsHumanstherapeutic transgeneVirotherapyoncolytic virusbusiness.industryImmunotherapyVirologyOncolytic virusImmuntherapie030104 developmental biologychemistryVacciniabusinessViruses
researchProduct

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of a…

2017

Lutz E Pillunat,1 Carl Erb,2 Auli Ropo,3 Friedemann Kimmich,4 Norbert Pfeiffer5 1Department of Ophthalmology, University Hospital Carl Gustav Carus, Dresden, 2Augenklinik am Wittenbergplatz, Berlin, Germany; 3Santen Europe, Helsinki, Finland; 4eyecons, Pfinztal, 5Department of Ophthalmology, Mainz University Medical Center, Mainz, Germany Background: Efficacy, tolerability and safety of the novel preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% (Taptiqom®) were investigated in an observational study in Germany.Objective: To assess efficacy, tolerability and safety of the preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% in a real-life setti…

030213 general clinical medicinemedicine.medical_specialtyIntraocular pressureOpen angle glaucomagenetic structuresfixed combinationGlaucomaTimololOcular hypertension03 medical and health sciences0302 clinical medicineOphthalmologymedicineAdverse effectOriginal Researchpreservative-free medicationbusiness.industrytafluprostTafluprostClinical Ophthalmologymedicine.diseasetimololeye diseasesOphthalmologyglaucomaTolerability030221 ophthalmology & optometrysense organspreservativesbusinessmedicine.drugClinical Ophthalmology (Auckland, N.Z.)
researchProduct